Company intelligence / Profile preview

Pharmaxis

Frenchs Forest/Sydney, NSW, Australiapharmaxisgroup.com ↗

Ownership: Private
Employees: ~90
Development stage: Phase 2

Overview

Pharmaxis has developed two commercial respiratory products—Bronchitol® for cystic fibrosis and Aridol® for asthma assessment—approved in multiple global markets. Its pipeline includes small molecule amine oxidase inhibitors targeting fibrotic and inflammatory diseases. Lead asset PXS‐5505 has Orphan Drug Designation from the FDA for myelofibrosis and entered Phase 1c/2 trials. Other programs target NASH and diabetic retinopathy via partnerships such as with Boehringer Ingelheim.

Therapeutic areas: PulmonologyImmunologyOtherOncologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

10 assets

Bronchitol

Approved

9 more assets in the full pipeline.

Request access →

Partnerships

Boehringer IngelheimWoolcock Institute of Medical ResearchUniversity of Sydney

Beyond the preview

Go deeper on Pharmaxis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmaxis.

Explore the full profile